Shanghai Junshi Biosciences Aktie

Kaufen

Verkaufen

3,02 EUR +0,12 EUR +4,14 %

07:19:38

FSE

3,06 EUR +0,16 EUR +5,52 %

07:26:56

HAML

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Marktkap.3,06 Mrd. EUR

Div. Rendite0,00%

WKNA2N9PC

ISINCNE100003FF7

SymbolSHJBF

Shanghai Junshi Biosciences Aktien News

Sortieren:Datum Meistgelesen

27.05.25GlobeNewswireJunshi Biosciences Announces Ongericimab’s sNDA Approval in China

25.04.25GlobeNewswireJunshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

29.03.25GlobeNewswireJunshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

27.03.25GlobeNewswireJunshi Biosciences Announces Toripalimab’s Approval in Singapore

24.03.25GlobeNewswireJunshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma

20.01.25GlobeNewswireJunshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

17.01.25GlobeNewswireJunshi Biosciences Announces Toripalimab’s Approval in Australia

16.11.24GlobeNewswireJunshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

15.10.24GlobeNewswireJunshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR

25.09.24GlobeNewswireJunshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

31.08.24GlobeNewswireJunshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates

12.08.24GlobeNewswireJunshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

26.07.24GlobeNewswireJunshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab

18.07.24GlobeNewswireJunshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

25.06.24GlobeNewswireJunshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC

18.06.24GlobeNewswireJunshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

12.06.24GlobeNewswireJunshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint

25.04.24GlobeNewswireJunshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

07.04.24GlobeNewswireJunshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

29.03.24GlobeNewswireJunshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates

02.02.24GlobeNewswireJunshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority

18.01.24GlobeNewswireJunshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cance

10.01.24GlobeNewswireJunshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medi

02.01.24GlobeNewswireJunshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients

02.12.23GlobeNewswireJunshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA

23.11.23GlobeNewswireJunshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

27.10.23GlobeNewswireJunshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023

31.08.23GlobeNewswireJunshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates

20.07.23GlobeNewswireJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer

12.07.23GlobeNewswireJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab

29.06.23GlobeNewswireJunshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

23.05.23GlobeNewswireJunshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer

07.05.23GlobeNewswireJunshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries

27.04.23GlobeNewswireJunshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

20.04.23GlobeNewswireJunshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung

Shanghai Junshi Biosciences News

Shanghai Junshi Biosciences News: auf dieser Seite finden Sie alle Shanghai Junshi Biosciences News und Nachrichten zur Shanghai Junshi Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Shanghai Junshi Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Shanghai Junshi Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.